FDA unveils new regulatory roadmap for bespoke drug therapies

The “plausible mechanism” pathway, outlined by Dr. Martin Makary and Dr. Vinay Prasad, is designed to help accelerate treatments custom-made for individuals with rare and serious diseases.

After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing

Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.